References
1. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol . 2010;11(5):429-438. doi:10.1016/S1470-2045(10)70066-8
2. Khabirova E, Jardine L, Coorens THH, et al. Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia. Nat Med . 2022;28(4):743-751. doi:10.1038/s41591-022-01720-7
3. Chen C, Yu W, Alikarami F, et al. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood . 2022;139(14):2198-2211. doi:10.1182/blood.2021013442
4. Tirtakusuma R, Szoltysek K, Milne P, et al. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. Blood . 2022;140(17):1875-1890. doi:10.1182/blood.2021015036
5. Meyer C, Larghero P, Almeida Lopes B, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia . Published online April 5, 2023. doi:10.1038/s41375-023-01877-1
6. Rossi JG, Bernasconi AR, Alonso CN, et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol . 2012;87(9):890-897. doi:10.1002/ajh.23266
7. Semchenkova A, Mikhailova E, Komkov A, et al. Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.Int J Mol Sci . 2022;23(7):4019. doi:10.3390/ijms23074019
8. Rayes A, McMasters RL, O’Brien MM. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy. Pediatr Blood Cancer . 2016;63(6):1113-1115. doi:10.1002/pbc.25953
9. Du J, Chisholm KM, Tsuchiya K, et al. Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); KMT2A/EPS15, Following Blinatumomab Therapy. Pediatr Dev Pathol . 2021;24(4):378-382. doi:10.1177/10935266211001308
10. Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol . 2019;37(25):2246-2256. doi:10.1200/JCO.19.00261
11. Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov . 2021;11(6):1440-1453. doi:10.1158/2159-8290.CD-20-1465
12. Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.Lancet Oncol . 2020;21(4):551-560. doi:10.1016/S1470-2045(20)30060-7
13. Brethon B, Lainey E, Caye-Eude A, et al. Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia. Front Oncol . 2021;11:637951. doi:10.3389/fonc.2021.637951
14. Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature . 2018;562(7727):373-379. doi:10.1038/s41586-018-0436-0
15. Peham M, Panzer S, Fasching K, et al. Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease. Br J Haematol . 2002;117(2):315-321. doi:10.1046/j.1365-2141.2002.03428.x
16. Van der Velden VHJ, Corral L, Valsecchi MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.Leukemia . 2009;23(6):1073-1079. doi:10.1038/leu.2009.17
17. Winters AC, Bernt KM. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr . 2017;5:4. doi:10.3389/fped.2017.00004
18. Ovilla-Martinez R, Weber Sánchez LA, Cota-Rangel X, Baez-Islas PE. Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia. BMJ Case Rep . 2021;14(11):e243745. doi:10.1136/bcr-2021-243745
19. Stutterheim J, van der Sluis IM, de Lorenzo P, et al. Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. J Clin Oncol . 2021;39(6):652-662. doi:10.1200/JCO.20.02333
20. van der Sluis IM, de Lorenzo P, Kotecha RS, et al. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. N Engl J Med . 2023;388(17):1572-1581. doi:10.1056/NEJMoa2214171